As a result of these investigations, and because irinotecan and topotecan are typically used as second-line therapy in SCLC, we finalized our candidate algorithms to the following two: 1) etoposide within 180 days of diagnosis and 2) etoposide plus no reported EGFR testing within 180 days of diagnosis. This evidence concerns the gene EGFR and small cell lung carcinoma.